Genflow Biosciences (GENF.L)

Executive Summary

Genflow Biosciences is a UK-based biotechnology company (listed as GENF.L) focused on developing gene therapies to slow or halt aging, targeting both humans and dogs. Founded in 2020 with R&D in Belgium and a US office in Cambridge, MA, its lead program leverages a centenarian variant of the SIRT6 gene, which has been linked to longevity. The company is in the pre-clinical stage, aiming to extend healthspan and lifespan. With a small market cap (~$14M) and a novel approach to aging, Genflow represents a high-risk, high-reward opportunity in the gene therapy space. Key upcoming milestones include initial preclinical proof-of-concept data and potential regulatory filings to advance toward clinical trials.

Upcoming Catalysts (preview)

• Q3 2026Preclinical efficacy data for SIRT6 gene therapy in aging models50% success
• TBDIND/CTA submission for first-in-human study30% success
• TBDStrategic partnership or licensing deal for canine longevity program40% success